HK1249858A1 - 响应於雷帕霉素和地塞米松诱导的标准和高葡萄糖条件禁食模仿膳食(fmd)和降葡萄糖药物保护正常细胞并产生癌症敏感条件 - Google Patents

响应於雷帕霉素和地塞米松诱导的标准和高葡萄糖条件禁食模仿膳食(fmd)和降葡萄糖药物保护正常细胞并产生癌症敏感条件 Download PDF

Info

Publication number
HK1249858A1
HK1249858A1 HK18109338.2A HK18109338A HK1249858A1 HK 1249858 A1 HK1249858 A1 HK 1249858A1 HK 18109338 A HK18109338 A HK 18109338A HK 1249858 A1 HK1249858 A1 HK 1249858A1
Authority
HK
Hong Kong
Prior art keywords
hyperglycemia
administered
chemotherapy
subject
diet
Prior art date
Application number
HK18109338.2A
Other languages
English (en)
Chinese (zh)
Inventor
瓦尔特‧D‧隆哥
瓦爾特‧D‧隆哥
斯特凡诺‧迪比亚斯
斯特凡諾‧迪比亞斯
Original Assignee
南加利福尼亚大学
南加利福尼亞大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南加利福尼亚大学, 南加利福尼亞大學 filed Critical 南加利福尼亚大学
Publication of HK1249858A1 publication Critical patent/HK1249858A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18109338.2A 2015-04-16 2016-04-18 响应於雷帕霉素和地塞米松诱导的标准和高葡萄糖条件禁食模仿膳食(fmd)和降葡萄糖药物保护正常细胞并产生癌症敏感条件 HK1249858A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562148451P 2015-04-16 2015-04-16
US62/148,451 2015-04-16
PCT/US2016/028055 WO2016168802A2 (en) 2015-04-16 2016-04-18 Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone

Publications (1)

Publication Number Publication Date
HK1249858A1 true HK1249858A1 (zh) 2018-11-16

Family

ID=57126369

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18109338.2A HK1249858A1 (zh) 2015-04-16 2016-04-18 响应於雷帕霉素和地塞米松诱导的标准和高葡萄糖条件禁食模仿膳食(fmd)和降葡萄糖药物保护正常细胞并产生癌症敏感条件

Country Status (14)

Country Link
US (2) US20160303056A1 (enExample)
EP (2) EP3283073A4 (enExample)
JP (2) JP2018511625A (enExample)
KR (1) KR20180002677A (enExample)
CN (1) CN107613979A (enExample)
AU (1) AU2016248443B2 (enExample)
BR (1) BR112017022244A2 (enExample)
CA (2) CA2982875C (enExample)
HK (1) HK1249858A1 (enExample)
IL (1) IL255026A0 (enExample)
MX (1) MX2017013133A (enExample)
RU (1) RU2734774C2 (enExample)
WO (1) WO2016168802A2 (enExample)
ZA (1) ZA201707710B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2724525C2 (ru) * 2015-05-06 2020-06-23 Юниверсити Оф Саутерн Калифорния Способ лечения повышенных уровней инсулина или глюкозы с использованием гипокалорийного или бескалорийного рациона или рациона, имитирующего воздержание от пищи
MX2018009849A (es) 2016-02-15 2018-11-09 Univ Southern California Combinaciones de farmacos y metodos para estimular regeneracion de tipo embrionaria para tratar diabetes y otras enfermedades.
MX2018013727A (es) 2016-05-11 2019-08-29 Univ Southern California Dieta imitadora del ayuno (fmd) como un tratamiento inmunoregulador para enfermedades gastrointestinales autoinmunes/inflamatorias.
WO2018102393A1 (en) * 2016-11-30 2018-06-07 Cure Cancer Worldwide Llc System for chemotherapy delivery and method of the same
US11284640B2 (en) * 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
WO2019178486A1 (en) 2018-03-15 2019-09-19 University Of Southern California Fasting-mimicking diet (fmd) but not water-only fasting promotes reversal of inflammation and ibd pathology
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
US20220400732A1 (en) * 2019-03-21 2022-12-22 Cornell University Anti-fructose therapy for colorectal and small intestine cancers
CN114096164A (zh) 2019-04-30 2022-02-25 南加利福尼亚大学 作为阿尔茨海默病(ad)的干预措施的禁食模拟饮食(fmd)
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
WO2021257465A1 (en) * 2020-06-14 2021-12-23 L-Nutra, Inc. An intermittent fasting bar/drink that maintains and extends the fasting state
EP4180047A4 (de) * 2020-07-10 2024-03-13 Martynova, Elena Anatol'evna Verfahren zur durchführung eines fastenverlaufs für schwerkranke patienten

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050302A2 (en) * 2009-10-22 2011-04-28 University Of Southern California Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment
BR112013014076A2 (pt) * 2010-12-06 2016-11-22 Cure Cancer Worldwide Corp métodos de direcionamento metabólico de células de câncer usando quimio- e imunotherapia para tratamento de câncer
US9237761B2 (en) * 2013-02-12 2016-01-19 University Of Southern California Methods and diets for lowering glucose and/or IGF-1 levels
RU2672594C2 (ru) * 2013-07-01 2018-11-16 Юниверсити Оф Саутерн Калифорния Состояние воздержания от пищи в качестве диетического лечения диабета
EP3113776B1 (en) * 2014-03-06 2021-01-13 University of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues

Also Published As

Publication number Publication date
JP2018511625A (ja) 2018-04-26
CN107613979A (zh) 2018-01-19
US20210137856A1 (en) 2021-05-13
ZA201707710B (en) 2019-04-24
RU2734774C2 (ru) 2020-10-23
RU2017136423A3 (enExample) 2019-09-04
MX2017013133A (es) 2018-09-07
IL255026A0 (en) 2017-12-31
CA2982875C (en) 2021-10-19
JP2021008491A (ja) 2021-01-28
EP4299061A3 (en) 2024-02-28
EP4299061A2 (en) 2024-01-03
RU2017136423A (ru) 2019-05-16
CA3108664A1 (en) 2016-10-20
BR112017022244A2 (pt) 2018-07-10
AU2016248443B2 (en) 2021-03-18
KR20180002677A (ko) 2018-01-08
EP3283073A2 (en) 2018-02-21
AU2016248443A1 (en) 2017-11-02
EP3283073A4 (en) 2019-02-13
CA2982875A1 (en) 2016-10-20
US20160303056A1 (en) 2016-10-20
WO2016168802A2 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
HK1249858A1 (zh) 响应於雷帕霉素和地塞米松诱导的标准和高葡萄糖条件禁食模仿膳食(fmd)和降葡萄糖药物保护正常细胞并产生癌症敏感条件
KR102811762B1 (ko) 상승된 콜레스테롤 수준 및/또는 상승된 ldl 수준의 감소용 금식 모방 규정식 조성물
AU2020200726B2 (en) Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
AU2010310515A1 (en) Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment
JP2021183622A (ja) 多発性骨髄腫及び他のがんに対する食事療法としての長期断食模倣の使用
HK40100962A (en) Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone
US12285453B2 (en) Fasting-mimicking diet promotes cancer-free survival in acute lymphoblastic leukemia models